gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TWSTHealthcareBiotechnology

Twist Bioscience Corporation Common Stock (TWST)

$142.58+1.63%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$142.58▲ 374.32% in range
Nov 4, 2025Low $25.45 · High $205.00Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Twist Bioscience closed at $142.58 on Nov 4, up 1.63%, 30.4% below its 52-week closing high. Volume of 2.0M shares was 0.75× its 20-day average (below normal).

Split-adjusted performance: -14.6% over one month, +139.5% over six months, +351.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $118.38M, up 23.2% from a year earlier, with a net margin of -29.6%.

Short interest was 10.2M shares at the Oct 15 settlement, down 3.4% from the prior report (16.6% of float, 2.8 days to cover).

Market cap$9.45B66.3M shares
Revenue · quarter$118.4M+23.2% YoY
Diluted EPS$-0.56−269.7% YoY
P/E · TTM—P/S 21.9×
Net margin-29.6%Gross 52.8%
Dividend yieldNone
52-week range25.45 – 205.00−30.4% from high
Volume2.0M0.75× 20-day avg
Volatility · 60d107.2%Annualised
Short % of float16.6%2.8 days to cover
Net cash$151.8MCash $166.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −17.8%1M −14.6%3M +30.7%6M +139.5%YTD +349.5%1Y +351.6%3Y +845.5%5Y +24.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum98
Revenue growth66
Net margin67
Value (low P/E)—
Size91

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short10.2M−3.4% vs prior
Days to cover2.8Settled Oct 15
% of float16.6%
Short vol. 10d55.8%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TWSTTwist Bioscience$142.58+1.63%+139.5%+23.2%−29.6%—$9.45B
IBRXImmunityBio$8.93+7.72%+6.6%+93.9%−449.6%—$9.46BCompare
KRYSKrystal Biotech$310.84+1.90%+7.6%+30.2%49.5%40.9$9.20BCompare
PCVXVaxcyte$65.68+8.01%+15.0%———$10.34BCompare
RGENRepligen$178.20−0.04%+41.7%+10.9%−18.4%—$11.31BCompare
TECHBio-Techne$72.73+0.10%+53.4%+1.3%17.0%62.8$11.42BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare
KODKodiak Sciences$98.51−0.38%+114.7%———$6.19BCompare
IMVTImmunovant$29.90+2.96%+4.3%———$6.18BCompare

News about Twist Bioscience

All news →
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCelleraGlobeNewswire Inc. · Oct 12, 2026▲ PositiveWhy Twist Bioscience Stock Skyrocketed This WeekThe Motley Fool · Sep 18, 2026▲ Positive

Quick answers

What does Twist Bioscience do?
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale.
What is TWST's market cap?
$9.45B, based on the Nov 4 close of $142.58.
Does Twist Bioscience pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TWST is sold short?
10.2M shares, 16.6% of float, as of Oct 15, 2026.
What sector is TWST in?
Healthcare, in the Biotechnology industry.

About Twist Bioscience

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

HQ: South San Francisco, CA979 employeesListed Oct 31, 2018twistbioscience.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology